Advertisement Synageva names new CEO and opens new headquarters - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

Synageva names new CEO and opens new headquarters

Synageva BioPharma, which focuses on the development of biopharmaceuticals for the treatment of oncology, autoimmune and genetic diseases, has appointed Sanj Patel as its new president and CEO.

In conjunction with Mr Patel’s appointment, Synageva has opened new corporate headquarters outside of Boston in Waltham, Massachusetts. The company maintains research and production operations in the greater Atlanta area where the company was originally founded under the name of Avigenics.

Mr Patel joins Synageva BioPharma from Genzyme. Most recently, Mr Patel was head of US sales, marketing and commercial operations for Genzyme Therapeutics and led the commercial US launch for Myozyme.

Mr Patel has obtained his BSc with honors in pure and applied biotechnology from South Bank University, London and his post-graduate management and business degree and training from Ealing College, London.

Felix Baker, chairman of the board at Synageva, said: “Sanj’s industry experience, particularly in managing the clinical development and commercialization of key biopharmaceutical products for Genzyme, makes him an excellent fit to lead Synageva.”